CA Patent

CA2700835A1 — Solid forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use

Assigned to Tersera Therapeutics LLC · Expires 2009-04-02 · 17y expired

What this patent protects

Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-tri-fluoroethoxy)pyrimidin-4-yl)phenyl)propanoate and salts thereof are disclosed.

USPTO Abstract

Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-tri-fluoroethoxy)pyrimidin-4-yl)phenyl)propanoate and salts thereof are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
CA2700835A1
Jurisdiction
CA
Classification
—
Expires
2009-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Tersera Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.